Tags

Type your tag names separated by a space and hit enter

An assessment by the Statin Liver Safety Task Force: 2014 update.
J Clin Lipidol. 2014 May-Jun; 8(3 Suppl):S47-57.JC

Abstract

In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.

Authors+Show Affiliations

Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. Electronic address: hbaysmd@aol.com.Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.Indiana University School of Medicine, Indianapolis, IN, USA.Brooke Army Medical Center, University of Texas Health Center San Antonio, Uniformed Services University of the Health Sciences, San Antonio, TX, USA.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

24793441

Citation

Bays, Harold, et al. "An Assessment By the Statin Liver Safety Task Force: 2014 Update." Journal of Clinical Lipidology, vol. 8, no. 3 Suppl, 2014, pp. S47-57.
Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47-57.
Bays, H., Cohen, D. E., Chalasani, N., Harrison, S. A., & The National Lipid Association's Statin Safety Task Force, . (2014). An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology, 8(3 Suppl), S47-57. https://doi.org/10.1016/j.jacl.2014.02.011
Bays H, et al. An Assessment By the Statin Liver Safety Task Force: 2014 Update. J Clin Lipidol. 2014;8(3 Suppl):S47-57. PubMed PMID: 24793441.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An assessment by the Statin Liver Safety Task Force: 2014 update. AU - Bays,Harold, AU - Cohen,David E, AU - Chalasani,Naga, AU - Harrison,Stephen A, AU - The National Lipid Association's Statin Safety Task Force,, PY - 2014/02/27/received PY - 2014/02/28/accepted PY - 2014/5/6/entrez PY - 2014/5/6/pubmed PY - 2014/12/17/medline KW - Cholesterol KW - Lipid KW - Liver KW - National Lipid Association KW - Statin SP - S47 EP - 57 JF - Journal of clinical lipidology JO - J Clin Lipidol VL - 8 IS - 3 Suppl N2 - In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes. SN - 1933-2874 UR - https://www.unboundmedicine.com/medline/citation/24793441/An_assessment_by_the_Statin_Liver_Safety_Task_Force:_2014_update_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1933-2874(14)00073-7 DB - PRIME DP - Unbound Medicine ER -